Abstract. Inhibitor of growth family member 4 (ING4) is a candidate tumor suppressor that serves important roles in tumor growth and angiogenesis. In the present study ING4 expression was assessed in clear cell renal carcinoma (CCRC) tissues and its association with the progression of CCRC was determined. The expression of ING4 in 125 patients with CCRC was analyzed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), western blot analysis and immunohistochemical methods. A total of 40 adjacent normal renal tissues were used as control samples. The results identified that ING4 expression was positive in 100% of normal renal tissues, but in only 82.3% CCRC samples. RT-qPCR and western blotting results demonstrated that expression levels of ING4 mRNA and protein were significantly decreased in CCRC compared with in normal tissues (P<0.0001). ING4 expression was not associated with sex, age or tumor volume (P>0.05), but was associated with the nuclear grade of renal cancer (P<0.0001), the clinical stage of CCRC (P<0.0001) and lymphatic metastasis (P<0.0001). The results of the present study indicated that dysregulation of ING4 expression may be involved in the initiation and progression of CCRC.
Introduction
Inhibitor of growth (ING) is a family of tumor suppressor genes, and the well-known members of this family are inhibitor of growth family member 1 (ING1), ING2, ING3, ING4 and ING5 (1, 2) . The ING4 gene is localized at chromosome 12p13, consists of 8 exons and encodes a 29-kDa nuclear protein; its expression is ubiquitous in multiple different human tissues (3) (4) (5) . The biological functions of ING4 have been extensively investigated, with a previous study demonstrating that ING4 protein promoted tumor protein p53 activity through direct interaction with it (6) . As a consequence of the interaction between ING4 and p53, tumor protein p21 expression was upregulated, leading to cell cycle arrest (7, 8) . In addition, ING4 altered apoptosis, contact inhibition and DNA repair (9, 10) . ING4 has been considered as an important tumor suppressor gene, whose expression was significantly downregulated in a number of malignant tumors, including breast cancer, glioma and lung cancer (8, 11, 12) . However, the expression of ING4 has not been investigated in renal cell carcinoma. Approximately 15 million people worldwide are diagnosed with renal cell carcinoma annually (13) , of which 75% of cases are clear cell renal carcinoma (CCRC) (14) . The molecular mechanism of renal cell carcinoma has been extensively investigated, but there is no targeted therapy owing to a lack of targets. As ING4 was downregulated, or even mutated, in multiple cancer types (8, 15, 16) , In the present study, ING4 was inferred to be associated with multiple cancer types, potentially making it an ideal target for cancer therapy. In the present study, the level of ING4 mRNA and protein was probed in renal cancer tissue specimens in 125 patients with CCRC, and the adjacent normal tissue from 40 patients were used as a control. Western blotting. Western blotting was performed to detect the protein level of ING4 in the renal tissues obtained from the 40 patients. Tissue samples of ~50 mg were minced and ground in liquid nitrogen. The proteins were extracted using a Protein Extraction kit (Pierce; Thermo Fisher Scientific, Inc.), and the protein concentration was determined using the Bradford assay. A total of 100 µg protein was separated by SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were blocked with 5% skimmed milk powder in PBS and subsequently incubated with rabbit anti-human ING4 polyclonal antibody (1:300; cat no. 40-7700; Invitrogen; Thermo Fisher Scientific, Inc.). Following washing, the membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit antibody (1:10,000; cat no. ZB-5301; Beijing Zhongshan Biotechnology Jinqiao Co., Ltd., Beijing, China). An enhanced chemiluminescence detection system (Shanghai Jiapeng Technology Co., Ltd., Shanghai, China) was used to visualize the protein bands. β-actin (1:1,000; cat no. ab8226; Abcam, Cambridge, MA, USA) was used as an internal control. All experiments were repeated three times independently, and the level of ING4 protein expression was quantified using Scion imaging software 4.0 (Scion Corporation, Frederick, MD, USA).
Materials and methods

Patients
Immunohistochemistry (IHC) analysis. IHC analysis was performed using a two-step immunohistochemical staining protocol as previously described (19) . Briefly, 4-µm-thick sections were blocked with 5% bovine serum albumin in PBS prior to incubation overnight at 4˚C with rabbit anti-human (Fig. 3B-F) . The spatial expression of ING4 and the nuclear grade of CCRC is presented in Table I . The results indicated that ING4 protein expression was inversely associated with the nuclear grade of CCRC, and the rate of ING4 expression was increased with a low nuclear grade of CCRC (P<0.0001). No association was identified between ING4 expression and the sex, age, tumor size and clinical stage of the patients (P>0.05; Table II) .
Discussion
ING is a family of tumor suppressor genes that includes ING1, ING2, ING3, ING4 and ING5. These genes participate in a number of cellular events, including the cell cycle, apoptosis and DNA repair. Overexpression of ING4 disrupted the cell cycle distribution of the cells, decreasing the number of cells in S phase (7) . As a tumor suppressor gene, ING4 expression can suppress the growth of gliomas, breast tumors and squamous cell carcinomas of the head and neck (4, 5) ; however, its roles in CCRC remain unclear. In the present study, 125 clinical CCRC specimens underwent western blot analysis, RT-qPCR and IHC to probe ING4 expression in CCRC. The results of these analyses revealed that ING4 expression was significantly decreased in CCRC tissues compared with in the normal renal tissues at the mRNA and protein levels. ING4 was expressed in 100% of normal renal tissue samples (40/40 cases), but its expression was detectable only in 49.6% of CCRC samples (62/125). Garkavtsev et al (3) identified that the expression of ING4 mRNA in 50 glioma samples was significantly decreased compared with that in 5 adjacent brain tissues. Previous studies indicated that ING4 was downregulated in prostate cancer cell lines, melanoma, and in cancer of the stomach, liver, breast and lung (15, 16, (20) (21) (22) and in 76% of the head and neck squamous cell carcinoma samples assessed (4) . Taken together, the results of the present study indicated that a decrease in ING4 expression was associated with a variety of tumors, including CCRC. Besides the dysregulation of ING4 expression, deletions and missense mutations in ING4 transcripts were detected in several tumor cell lines (4) . Hybridization-mediated deletion of the ING4 locus was identified in between 10 and 20% of breast cancer cell lines and primary breast tumors, and in 66% (23) , suggesting that alternative splicing events may be one of the reasons for the cytoplasmic localization of ING4 in renal cancer.
ING4-positive a --------------------------------------------------------------------------
Renal cell carcinoma does not typically respond to chemotherapy or radiation therapy, but responds well to immunotherapy (24) . Therefore, it is important to develop novel therapeutic approaches for the treatment of CCRC. On the basis of the conclusions drawn from studies of other tumors, ING4 may serve as a valuable marker for CCRC, particularly the membrane-bound ING4 splicing variants, which may be targets for future immunotherapy strategies.
In conclusion, the results of the present study demonstrated that ING4 expression was downregulated in CCRC, and its expression was identified for the first time, to the best of our knowledge, to be associated with the advancement of clinical stage and nuclear grade level. Considering its roles in other types of tumor, ING4 may be a novel target for the diagnosis and therapy of CCRC.
